Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Victoria's Secret & Co (VSXY) Price & Performance

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.

Victoria's Secret (VSXY) trades at $88.82, up 0.26% today, with strong technical momentum showing bullish moving averages and key support at $87. The company demonstrates improving fundamentals with three consecutive quarterly earnings beats and a robust 45.27% ROE, though net margins remain modest at 5.47%. Recent news highlights brand momentum through fashion show expansions and omnichannel growth strategies, with the stock surging 6.5% on September 28, 2026.

VSXY presents a mixed outlook with accelerating growth projections for 2026 but faces valuation concerns at a P/E of 19.83. Analyst consensus leans bullish with 60% buy ratings and a $86.80 price target, though the current price exceeds this target. Key risks include rich valuation, rising costs, and competitive pressures in retail apparel, while institutional accumulation and strong cash flow projections for 2026 provide support for long-term investors.